ClinicalTrials.gg
Not yet recruitingNCT07948122BIG2Updated Nov 19, 2026

Prospective Evaluation of Response to Treatment in Younger Adult Patients (18-60 Years) With Acute Myeloid Leukemia (AML)

A Phase 3 interventional study of Quizartinib and Midostaurin in Acute Myeloid Leukemia, sponsored by University Hospital, Toulouse. Not yet recruiting at 55 sites in France. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by University Hospital, Toulouse · Phase 3, Interventional, and Treatment

How we know

Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,290
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 342 studies in Leukemia, Myeloid, Acute with a site in France — 64 open to participants now, 96 under way, 21 of them phase 3. Leukemia, Myeloid, Acute · France.

Planned enrollment
4th of 289
1,290 · median 100
Started
2027
the only one that year
Phase 3
77 of 342
9 open now
Primary completion
2035-12
later than 94 of 95 live
Registered
342nd of 342
by date

Among the 342 studies in Leukemia, Myeloid, Acute with a site in France, this one is the 4th largest by planned enrollment of the 289 interventional ones that give a count, is the only one that started in 2027, is one of 77 in phase 3, reaches primary completion later than 94 of the 95 other live ones, and was the 342nd registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 813 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

64 of the 342 studies in Leukemia, Myeloid, Acute with a site in France are open now. Recruiting first, the newest first:

59 more — sign in →

All 64 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 621 Leukemia, Myeloid, Acute studies recruiting now, 361 (58%) set no upper age limit and 220 (35%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 342 studies in Leukemia, Myeloid, Acute with a site in France, or all of them as a file.
02

Study summary

The treatment of younger AML patients fit for intensive chemotherapy (IC) has long been based on a combination of an anthracycline and cytarabine as induction, followed by high-dose cytarabine (HDAC) consolidation, and possibly allogeneic stem-cell transplantation at least in non-favorable risk AML patients. Even if new agents like gemtuzumab ozogamicin (GO), FLT3 inhibitors, or CPX-351 have been approved to treat some patient subsets, there has been no major therapeutic advances to date in this field.

The first multicenter trial from the ALFA-FILO intergroup (Backbone InterGroup trial-1, BIG-1; NCT02416388; PHRC2010-03) randomly explored various standard intensive chemotherapy strategies, including higher-dose idarubicin vs. high-dose daunorubicin (DNR) and intermediate-dose cytarabine (IDAC) vs. HDAC in patients (18-60 years) with newly-diagnosed AML. This first part of the study, which enrolled 1405 participants between 01/2015 and 05/2019, showed that the benefit/risk ratio favored high-dose DNR for remission induction and IDAC consolidation, establishing the national standard treatment for younger AML patients. Six-year OS was 53.4% showing that there is still considerable room for improvement in this younger patient population.

High-throughput sequencing and multiparametric flow cytometry have significantly improved prognostic classifications and the evaluation of response to therapy through the quantification of measurable residual disease (MRD). Many studies have shown that the higher the MRD, the higher the risk of relapse and death; and recent guidelines have included MRD in the response criteria. Achieving complete remission without MRD is a major goal after first-line treatment to guide subsequent treatments, including transplantation. Furthermore, MRD follow-up in patients who achieved complete remission is becoming a major issue, as patients treated for molecular relapse appear to have a better prognosis than patients treated for morphological relapse. Preliminary data also showed encouraging results from salvage treatment at the time of MRD relapse.

Quizartinib (a second-generation FLT3-ITD inhibitor) and venetoclax (the first-in-class BCL-2 inhibitor) have been recently approved for the treatment of AML. Quizartinib was approved on the basis of a placebo-controlled trial but its added value compared to midostaurin (first FLT3 inhibitor available in this indication since 2018) has never been prospectively explored. Although venetoclax was approved for first line therapy of patients who are unfit for intensive chemotherapy, it is widely used in relapsed or refractory younger patients. Venetoclax combined with intensive salvage chemotherapy is feasible and induce a high rate of CR. However, no prospective, randomized trial demonstrated venetoclax efficacy in this setting.

Read the detailed description

Multicenter umbrella trial integrating 3 sub-studies with eligibility criteria based on molecular diagnosis and an MRD-guided treatment program.

  • The sub-study 1 (FLT3-ITD+ without CBF comparative study) is an open-label randomized controlled study
  • The sub-study 2 (FLT3-ITD- salvage comparative study) is an open-label randomized controlled study
  • The sub study 3 (FLT3-ITD- responders exploratory study) : open label single arm study
03

Conditions studied

  • Acute Myeloid Leukemia

Keywords

  • Umbrella Trial
  • Acute Myeloid Leukemia
  • Younger adult patients
  • Measurable Residual Disease
  • Intensive chemotherapy
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years and \< 61 years
  2. With a newly diagnosed de novo acute myeloid leukemia, or secondary acute myeloid leukemia arising from a previously known myelodysplastic syndrome, or post cytotoxic therapy-related acute myeloid leukemia, according to the 2022 World Health Organisation classification
  3. No prior treatment for acute myeloid leukemia (with the exception of hydroxyurea) or for myelodysplastic syndrome (with the exception of hematopoietic growth factors)
  4. performance status ≤ 3
  5. Eligible to induction chemotherapy
  6. No to anthracyclines: decompensated or uncontrolled heart failure, recent myocardial infarction, current signs of cardiac impairment, uncontrolled arrhythmias, or \< 50%
  7. Total ≤ 2 x , and Alanine Aminotransferase ≤ 2.5 X upper limit of normal, creatinine \< 150 µmol/l, unless acute myeloid leukemia-related values
  8. Women of should use appropriate methods of
  9. Health insurance coverage
  10. Signed written

Additional inclusion criteria for sub-study 1 11 1. Presence of FLT3 internal tandem duplication activating mutation in bone marrow (allelic ratio ≥ 0.03) 12-1. Receiving standard 7+3 induction chemotherapy regimen as specified in the protocol 13 1. Serum electrolytes within the institution's normal limits: potassium, calcium (total calcium, calcium corrected for serum albumin in case of hypoalbuminemia, or ionized calcium), and magnesium.

Additional inclusion criteria for sub-study 2 11-2. (no response) or CR/CRh/CRi with positive Measurable Residual Disease by Multiparameter Flow Cytometry in bone marrow (≥ 0.1%) after one cycle of 7+3 induction 12 2. Eligible for a second cycle of intensive chemotherapy

Additional inclusion criteria for sub-study 3 11 3. CR/CRh/CRi without Measurable Residual Disease by Multiparameter Flow Cytometry in bone marrow (\< 0.1% OR \< Limit of Detection) after one cycle of 7+3 induction.

Exclusion criteria

Exclusion Criteria:

  1. Patients with secondary acute myeloid leukemia arising from a previously known myeloproliferative neoplasm according to the 2022 World Health Organisation classification
  2. Patients with acute promyelocytic leukemia, as confirmed either by t(15;17) or by the presence of promyelocytic leukemia::RARA fusion transcripts
  3. Patients with t(9;22)(q34.1;q11.2)/BCR::ABL1 or previous Ph1+ disorder (chronic myelogenous leukemia)
  4. Severe psychiatric or organic disorder, supposed to be independent from acute myeloid leukemia , that would contraindicate treatment, including hematopoietic stem cell transplantation
  5. Any psychological, familial, social, or geographic reason that would compromise clinical follow up
  6. Prior cancer, if not stable for at least two years, except in-situ carcinoma and skin carcinoma
  7. With uncontrolled severe infection at study entry
  8. Patients with uncontroled -1 and -2 infection, or active hepatitis virus B or C infection
  9. Pregnant or lactating women
  10. Legal incapacity (patients under tutorship, curatorship or judicial protection)

Additional exclusion criteria for sub-study 1 11 1. Patients with Core-Binding Factor Acute myeloid leukemia 12 1. Prior treatment with quizartinib or other FLT3 inhibitors 13 1. Uncontrolled or significant cardiovascular disease, including any of the following:

  • Bradycardia \< 50 beats per minute
  • interval >450 msec
  • Diagnosis of or suspicion of long QT syndrome (including family history of long QT syndrome)
  • Systolic blood pressure ≥180 mm Hg or diastolic blood pressure ≥110 mm Hg
  • History of ventricular arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation, or torsade de pointes)
  • History of second (Mobitz II) or third-degree heart block (patients with pacemakers were eligible if they had no history of fainting or clinically relevant arrhythmias while using the pacemaker)
  • History of uncontrolled angina pectoris or myocardial infarction within 6 months before screening
  • History of class 3 or 4 heart failure
  • ≤45% or less than the institutional lower limit of normal per multigated acquisition scan or echocardiogram done within 30 days before randomization
  • Complete left bundle branch block 14-1. Uncorrected Grade 3 or 4 hypokalemia, hypomagnesemia or hypocalcemia. Subjects with Grade 1 or 2 electrolyte abnormalities can be enrolled while electrolytes are being corrected.

15-1. Treatment with any strong or moderate inducers within 2 weeks or 5 half-lives of randomization whichever is longer

Additional exclusion criteria for sub-study 2 11 2. Patients with acute myeloid leukemia with FLT3 internal tandem duplication mutation without Core-Binding Factor 12 2. Uncontrolled infection such as sepsis, or multiple organ dysfunction syndrome, uncontrolled fever 13 2. Documented uncontrolled fungal infection (positive blood test and cultures) 14 2. Prior venetoclax exposure

Additional exclusion criteria for sub-study 3 11 3. Patients with acute myeloid leukemia with FLT3 internal tandem duplication mutation without Core-Binding Factor

Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,290 participants (estimated)

Study arms

  • Experimental
    Quizartinib arm (sub study 1)

    Addition of quizartinib to induction chemotherapy (7+3) and consolidation chemotherapy (intermediate-dose cytarabine) in patients 18-60 years of age with newly diagnosed FLT3 internal tandem duplication Acute Myeloid Leukemia without Core Binding Factor Acute Myeloid Leukemia.

    Drug: Quizartinib

  • Experimental
    Midostaurin arm (sub study 1)

    Addition of midostaurin to induction chemotherapy (7+3) and consolidation chemotherapy (intermediate-dose cytarabine) in patients 18-60 years of age with newly diagnosed FLT3 internal tandem duplication Acute Myeloid Leukemia without Core Binding Factor Acute Myeloid Leukemia.

    Drug: Midostaurin

  • Experimental
    Venetoclax + high-dose cytarabine arm (sub study 2)

    Addition of venetoclax to high-dose cytarabine after one cycle of induction in patients 18-60 years of age with newly diagnosed FLT3 internal tandem duplication negative Acute Myeloid Leukemia (including Core Binding Factor Acute Myeloid Leukemia patients) and with a suboptimal response to 7+3 induction.

    Drug: Venetoclax

  • Active comparator
    High-dose cytarabine only (sub study 2)

    High-dose cytarabine only after one cycle of induction in patients 18-60 years of age with newly diagnosed FLT3 internal tandem duplication negative Acute Myeloid Leukemia (including Core Binding Factor Acute Myeloid Leukemia patients) and with a suboptimal response to 7+3 induction.

    Drug: High-dose cytarabine

  • No intervention
    Exploratory arm (sub study 3)

    MRD-guided program in patients 18-60 years of age with newly diagnosed FLT3 internal tandem duplication negative Acute Myeloid Leukemia (including Core Binding Factor Acute Myeloid Leukemia patients with FLT3 internal tandem duplication) and who achieved Complete Remission/Complete Remission with partial hematologic recovery/Complete Remission with incomplete hematologic recovery without Multiparameter Flow Cytometry for Measurable Residual Disease after one cycle of 7+3 induction.

Interventions

  • DrugQuizartinib

    Sub-study 1 : addition of quizartinib to induction chemotherapy (7+3) and to consolidation chemotherapy (intermediate-dose cytarabine) in patients 18-60 years of age with newly diagnosed FLT3 internal tandem duplication Acute Myeloid Leukemia without Core Binding Factor Acute Myeloid Leukemia.

  • DrugMidostaurin

    Sub-Study 1: Addition of midostaurin to induction chemotherapy (7+3) and consolidation chemotherapy (intermediate-dose cytarabine) in patients 18-60 years of age with newly diagnosed FLT3 internal tandem duplication Acute Myeloid Leukemia without Core Binding Factor Acute Myeloid Leukemia.

  • DrugVenetoclax

    Sub-Study 2 : Addition of venetoclax to high-dose cytarabine after one cycle of induction in patients 18-60 years of age with newly diagnosed FLT3 internal tandem duplication negative Acute Myeloid Leukemia (including Core Binding Factor Acute Myeloid Leukemia patients) and with a suboptimal response to 7+3 induction.

  • DrugHigh-dose cytarabine

    High-dose cytarabine after one cycle of induction in patients 18-60 years of age with newly diagnosed FLT3 internal tandem duplication negative Acute Myeloid Leukemia (including Core Binding Factor Acute Myeloid Leukemia patients) and with a suboptimal response to 7+3 induction.

06

What researchers measure

Primary outcomes

  1. Sub-Study 1 : MRD response

    Determine whether the addition of quizartinib to induction chemotherapy (7+3) results in a significant improvement in Measurable Residual Disease response after one cycle, as assessed by Polymerase Chain Reaction-Next-Generation Sequencing, compared to midostaurin added to 7+3 in patients 18-60 years of age with newly diagnosed FLT3 internal tandem duplication acute myeloid leukemia without Core-Binding Factor acute myeloid leukemia.

    Time frame: At the end of Cycle 1 (each cycle is 28 days)

  2. Sub-Study 2 : MRD response venetoclax

    Determine whether the addition of venetoclax to high-dose cytarabine results in a significant improvement in MRD response after one cycle, as assessed by MFC, compared to high-dose cytarabine alone in patients 18-60 years of age with newly diagnosed FLT3 internal tandem duplication negative acute myeloid leukemia (including Core-Binding Factor acute myeloid leukemia patients with FLT3 internal tandem duplication) and with a suboptimal response to 7+3 induction (i.e., no response or CR/CRh/CRi with positive Multiparameter Flow Cytometry for Measurable Residual Disease after one cycle of 7+3 induction).

    Time frame: At the end of Cycle 1 (each cycle is 28 days)

  3. Sub-Study 3 : Overall survival

    Describe the effect of an Measurable Residual Disease-guided program on overall survival in patients 18-60 years of age with newly diagnosed FLT3 internal tandem duplication negative acute myeloid leukemia (including Core-Binding Factor acute myeloid leukemia patients with FLT3 internal tandem duplication) who achieved CR/CRh/CRi without Multiparameter Flow Cytometry for Measurable Residual Disease after one cycle of 7+3 induction.

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 53 months

Secondary outcomes

  1. Sub-Study 1 : MRD response after 2 cycles

    Determine whether the addition of quizartinib to induction chemotherapy (7+3) and to consolidation chemotherapy results in a significant improvement in Measurable Residual Disease response after 2 cycles (combined induction and first consolidation, as assessed by Polymerase Chain Reaction-Next-Generation Sequencing, compared to the addition of Midostaurin in patients 18-60 years of age with newly diagnosed FLT3 internal tandem duplication acute myeloid leukemia without Core-Binding Factor acute myeloid leukemia.

    Time frame: At the end of Cycle 2 (each cycle is 28 days)

07

Study locations

55 sites
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Dec 2035, 107 months later.

Of 78 non-industry phase 3 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 87 months of starting (the median), counting those still running; a quarter within 66 and three quarters within 111. This study's planned 107 months is above that.

Counting every sponsor, half of 121 studies reached it within 74 months; a quarter within 39 and three quarters within 99.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2026
First posted
Nov 19, 2026
StartEst.
Jan 4, 2027
Primary completionEst.
Dec 31, 2035
CompletionEst.
Dec 31, 2037
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07948122
Responsible party
Sponsor
First posted
Nov 19, 2026
Start date
Jan 4, 2027 (estimated)
Primary completion
Dec 31, 2035 (estimated)
Completion
Dec 31, 2037 (estimated)
Last update
Nov 19, 2026

Study contacts

Christian RECHER, MD, PhD
Contact
Recher.Christian@iuct-oncopole.fr
0531156355 ext. 33
Christian RECHER, MD, PhD
study director · University Hospital, Toulouse

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion